Is Kamada Ltd. (KMDA) Overvalued?
We dive into why Kamada Ltd. (KMDA) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Commentary & Analysis
Why Kamada Ltd.’s (KMDA) Stock Is Up 5.89%
As of Thursday, August 13, Kamada Ltd.’s KMDA share price has surged by 5.89%, which has investors questioning if this is right time to sell.Michael Rose
What You Need to Know About Kamada Ltd.'s Q3 Earnings
Kamada Ltd.'s fiscal Q3 earnings report was released on Wednesday, August 12. Let's dive in to see if (KMDA) missed or beat analyst's expectations.Jenna Brashear
Why Kamada Ltd.’s (KMDA) Stock Is Down 8.83%
As of Wednesday, May 13, Kamada Ltd.’s KMDA share price has dipped by 8.83%, which has investors questioning if this is right time to buy.Jenna Brashear
What You Need to Know About Kamada Ltd.'s Q2 Earnings
Kamada Ltd.'s fiscal Q2 earnings report was released on Wednesday, May 13. Let's dive in to see if (KMDA) missed or beat analyst's expectations.Rosalio Madrigal
Financial Summary
| Share Statistics | KMDA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $458.2 | $286.3 | 36% |
|
| Shares Out (Mil) | 57.9 | 54.2 | 51% |
|
| Institutional Ownership | 80.4% | 92.8% | 49% |
|
| Float (Mil) | 31.5 | 39.7 | 37% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 214 | 534 | 45% |
|
| Price Change (52-week) |
10.6% | 58.7% | 54% |
|
| Growth | KMDA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.3% | 13.6% | 42% |
|
| Net Income (5yr) | 3.4% | (10.1%) | 45% |
|
| EPS (5yr) | (1.6%) | 16.0% | 29 |
|
| Dividends (5yr) | 0.0% | 0.0% | 62% |
|
| Cash Flow (5yr) | (15.8%) | (15.6%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | $0.133 | $0.488 | $0.597 | |
| Month Ago EPS | $0.125 | $0.428 | $0.613 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.125 | $0.428 | $0.613 | |
| Year/Year Chg | (16.9%) | 39.4% | 94.3% | |
| Financials | KMDA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $192 | $37 | 32% |
|
| Net Income (TTM) (Mil) | $22 | ($43) | 50% |
|
| EPS (TTM) | $0.381 | ($1.400) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | $36 | ($31) | 44% |
|
| Net Cash Flow (TTM) (Mil) | ($37) | $2 | 22% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | $352 | $160 | 31% |
|
| Valuation | KMDA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.72 | 2.77 | 45% |
|
| P/E | 21.0 | 19.1 | 53% |
|
| Dividend Yield | 3.1% | 0.0% | 85% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | KMDA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 40.8% | 64.2% | 51% |
|
| Net Margin | 11.6% | (75.9%) | 66% |
|
| ROA | 5.9% | (47.3%) | 75% |
|
| ROE | 8.4% | (55.0%) | 52% |
|
| Liabilities to Assets | 29.6% | 29.6% | 21% |
|
| F-Score | 7 | 2 | 82% |
|
Kamada Ltd. did not pass any screens on 8/20/2026.
